Press Release: Ventus : Ventus Therapeutics Announces Nature Reviews Immunology Publication Demonstrating the Promise of Caspase-4/5 as Therapeutic Targets

WALTHAM, Mass. & MONTREAL--(BUSINESS WIRE)--Ventus Therapeutics, a clinical-stage biopharmaceutical company with two novel small-molecule programs entering Phase 2 development for immunological, inflammatory, and neurological disorders, today announced a publication in the peer-reviewed journal Nature Reviews Immunology entitled "New insights into the noncanonical inflammasome point to caspase-4 as a druggable target." The article can be accessed here (doi: 10.1038/s41577-025-01142-9). Despite